These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 12079556)

  • 1. Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines.
    Mwau M; McMichael AJ; Hanke T
    AIDS Res Hum Retroviruses; 2002 Jun; 18(9):611-8. PubMed ID: 12079556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay.
    Dubey S; Clair J; Fu TM; Guan L; Long R; Mogg R; Anderson K; Collins KB; Gaunt C; Fernandez VR; Zhu L; Kierstead L; Thaler S; Gupta SB; Straus W; Mehrotra D; Tobery TW; Casimiro DR; Shiver JW
    J Acquir Immune Defic Syndr; 2007 May; 45(1):20-7. PubMed ID: 17310936
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the interlaboratory concordance in quantification of human immunodeficiency virus-specific T cells with a gamma interferon enzyme-linked immunospot assay.
    Samri A; Durier C; Urrutia A; Sanchez I; Gahery-Segard H; Imbart S; Sinet M; Tartour E; Aboulker JP; Autran B; Venet A;
    Clin Vaccine Immunol; 2006 Jun; 13(6):684-97. PubMed ID: 16760328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-clade T lymphocyte-mediated immunity to HIV type 1: implications for vaccine design and immunodetection assays.
    Keating SM; Bollinger RC; Quinn TC; Jackson JB; Carruth LM
    AIDS Res Hum Retroviruses; 2002 Sep; 18(14):1067-79. PubMed ID: 12396458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC.
    Kierstead LS; Dubey S; Meyer B; Tobery TW; Mogg R; Fernandez VR; Long R; Guan L; Gaunt C; Collins K; Sykes KJ; Mehrotra DV; Chirmule N; Shiver JW; Casimiro DR
    AIDS Res Hum Retroviruses; 2007 Jan; 23(1):86-92. PubMed ID: 17263637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials.
    Cox JH; Ferrari G; Kalams SA; Lopaczynski W; Oden N; D'souza MP;
    AIDS Res Hum Retroviruses; 2005 Jan; 21(1):68-81. PubMed ID: 15665646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continents.
    Boaz MJ; Hayes P; Tarragona T; Seamons L; Cooper A; Birungi J; Kitandwe P; Semaganda A; Kaleebu P; Stevens G; Anzala O; Farah B; Ogola S; Indangasi J; Mhlanga P; Van Eeden M; Thakar M; Pujari A; Mishra S; Goonetilleke N; Moore S; Mahmoud A; Sathyamoorthy P; Mahalingam J; Narayanan PR; Ramanathan VD; Cox JH; Dally L; Gill DK; Gilmour J
    Clin Vaccine Immunol; 2009 Feb; 16(2):147-55. PubMed ID: 19091991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy.
    Asjö B; Stavang H; Sørensen B; Baksaas I; Nyhus J; Langeland N
    AIDS Res Hum Retroviruses; 2002 Dec; 18(18):1357-65. PubMed ID: 12487807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
    Dean GA; LaVoy A; Burkhard MJ
    Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ELISPOT assay for detection of peptide specific interferon-gamma secreting cells in rhesus macaques.
    Kumar A; Weiss W; Tine JA; Hoffman SL; Rogers WO
    J Immunol Methods; 2001 Jan; 247(1-2):49-60. PubMed ID: 11150536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statistical evaluation for detection of peptide specific interferon-gamma secreting T-cells induced by HIV vaccine determined by ELISPOT assay.
    Periwal SB; Spagna K; Shahabi V; Quiroz J; Shroff KE
    J Immunol Methods; 2005 Oct; 305(2):128-34. PubMed ID: 16181634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects.
    Sanou MP; Roff SR; Mennella A; Sleasman JW; Rathore MH; Yamamoto JK; Levy JA
    J Virol; 2013 Sep; 87(18):10004-15. PubMed ID: 23824804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus.
    Smith JG; Liu X; Kaufhold RM; Clair J; Caulfield MJ
    Clin Diagn Lab Immunol; 2001 Sep; 8(5):871-9. PubMed ID: 11527795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.
    Sambor A; Garcia A; Berrong M; Pickeral J; Brown S; Rountree W; Sanchez A; Pollara J; Frahm N; Keinonen S; Kijak GH; Roederer M; Levine G; D'Souza MP; Jaimes M; Koup R; Denny T; Cox J; Ferrari G
    J Immunol Methods; 2014 Jul; 409():107-16. PubMed ID: 24787274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials.
    Shafer-Weaver K; Rosenberg S; Strobl S; Gregory Alvord W; Baseler M; Malyguine A
    J Immunother; 2006; 29(3):328-35. PubMed ID: 16699376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled-Peptide Epitope Mapping Strategies Are Efficient and Highly Sensitive: An Evaluation of Methods for Identifying Human T Cell Epitope Specificities in Large-Scale HIV Vaccine Efficacy Trials.
    Fiore-Gartland A; Manso BA; Friedrich DP; Gabriel EE; Finak G; Moodie Z; Hertz T; De Rosa SC; Frahm N; Gilbert PB; McElrath MJ
    PLoS One; 2016; 11(2):e0147812. PubMed ID: 26863315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions.
    Smith JG; Joseph HR; Green T; Field JA; Wooters M; Kaufhold RM; Antonello J; Caulfield MJ
    Clin Vaccine Immunol; 2007 May; 14(5):527-37. PubMed ID: 17376862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunodominance in CD8+ T cell responses to HIV-1 synthesized epitopes].
    Tang YB; Tang XP; Jin X
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Sep; 21(3):217-9. PubMed ID: 17971925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials.
    Bull M; Lee D; Stucky J; Chiu YL; Rubin A; Horton H; McElrath MJ
    J Immunol Methods; 2007 Apr; 322(1-2):57-69. PubMed ID: 17382342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.